Introduction {#sec1_1}
============

Although primary lymphoma of the gastrointestinal tract is rare, it remains one of the primary extranodal lymphoma sites. Primary gastrointestinal lymphoma involves any portion of the gastrointestinal tract from the mouth to the anal verge \[[@B1], [@B2]\]. It can present in one or multiple sites with local or distant lymph node involvement \[[@B3]\]. Most gastrointestinal lymphomas are of the non-Hodgkin type and account for about 1--4% of gastrointestinal tract malignant tumors \[[@B4]\]. About 75% of gastrointestinal tract lymphomas are found in the stomach, making it the most common site of extranodal involvement \[[@B5]\]. Only 3% of gastric neoplasms are primary lymphomas \[[@B6]\].

Gastric lymphoma does not have a typical presentation. The most common presenting symptoms, which might evolve within days to months, include epigastric pain (78%), anorexia (47%), weight loss (24%), gastrointestinal bleeding (19%), nausea and vomiting (18%) and occasionally diarrhea (4%). Gross upper gastrointestinal bleeding including hematemesis and melena are rare. About 4% of patients are asymptomatic \[[@B5]\].

Gastric lymphoma is usually diagnosed with upper endoscopy and biopsy. Surgical interventions are reserved for patients with complications. More than 90% of gastric lymphoma are divided into two histologic subtypes: the mucosa-associated lymphoid tissue (MALT) type (38--48%) and the diffuse large B cell type (45--59%) \[[@B7]\]. While the former responds well to *Helicobacter pylori* eradication, the latter is more aggressive, requiring extensive diagnostic workup and lengthy therapeutic intervention. The most common type of the remaining 10% of the gastric lymphomas include mantle cell, follicular and peripheral T cell forms \[[@B5], [@B7]\].

Primary diffuse large B cell lymphoma (DLBCL) is an aggressive type accounting for approximately 40% of all B cell malignancies \[[@B8]\]. Most DLBCLs have genetic abnormalities. There is no single cytogenetic change which is considered to be typical or diagnostic. DLBCLs demonstrate arrangement changes of both heavy and light chains of the immunoglobulin genes as well as somatic mutations of the variable region \[[@B9], [@B10]\]. Confirmation of the DLBCL is usually done with histochemistry or flow cytometry. Tumor cells in DLBCLs manifest themselves mostly in the B cell antigens, including CD19, CD20, CD22, CD79a and CD45 \[[@B11]\].

The treatment options for gastrointestinal DLBCL include surgery, radiation, chemo-immunotherapy and eradication of *H. pylori* infection. Combinations of these therapies may be utilized in certain cases. The majority of patients are treated with combination chemo-immunotherapy regimens similar to the one used for non-gastrointestinal DLBCL. Patients who present with perforation, obstruction or recurrent bleeding require surgical interventions \[[@B12], [@B13], [@B14], [@B15]\].

Case Presentation {#sec1_2}
=================

A 58-year-old diabetic man with dyspepsia was admitted because of weakness, dull abdominal pain and 10 kg weight loss within 3 months. He was on oral hypoglycemic agents and a proton pump inhibitor. His family history was unremarkable. The patient looked pale with the following vital signs: temperature 36.6°C, heart rate 97 bpm, respiratory rate 16/min, blood pressure 118/76 mm Hg and oxygen saturation on room air 100%. Epigastric tenderness was noted without rebound, organomegaly or palpable masses. Laboratory evaluation showed white blood cells 6.2 × 10^9^/l (range 4.5--10) with 60% neutrophils and 20% lymphocytes, hemoglobin 102 g/l (range 117--155), platelets 321 × 10^9^/l (range 140--400), glucose 4 mmol/l (range 3.9--6.1), sodium 137 mmol/l (range 135--145), potassium 4.4 mmol/l (range 3.4--5.1), bicarbonate 23 mmol/l (range 22--29), serum creatinine 57 μmol/l (range 59--104), calcium 2.25 mmol/l (range 2.2--2.5) and serum lactate dehydrogenase 313 IU/l (range 135--225). The rest of his laboratory workup was unremarkable. The patient had an abdominal computed tomography (CT) scan showing diffuse asymmetric wall thickening of the pylorus and antrum of the stomach as well as of the first part of the duodenum (fig. [1](#F1){ref-type="fig"}). He subsequently underwent esophagogastroduodenoscopy (EGD) revealing a large deep friable gastric ulcer with a clean base occupying about 75% of the antrum (fig. [2](#F2){ref-type="fig"}). Multiple tissue biopsies were obtained and histopathology testing, with immunohistochemistry, confirmed the diagnosis of DLBCL (fig. [3](#F3){ref-type="fig"}). The patient had a bone marrow aspiration with flow cytometry reported to be normal. CT scan of the chest and magnetic resonance imaging (MRI) of the brain were negative. A positron emission tomography scan confirmed a large gastric mass as well as several regional and mesenteric lymph nodes. His disease was staged as IV-A bulky high-grade primary gastric DLBCL (PG-DLBCL) with an International Prognostic Index score of 2/5. He had mild gastrointestinal bleeding complication after starting chemotherapy treatment requiring only blood transfusion. The patient received a total of eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone (R-CHOEP). 14 months post treatment, the repeat lactate dehydrogenase level was 130 IU/l, while a CT scan of the abdomen revealed resolution of the previous gastroduodenal thickening (fig. [4](#F4){ref-type="fig"}). Follow-up EGD showed complete healing of the antral ulcer (fig. [5](#F5){ref-type="fig"}). Histopathology confirmed the patient\'s total remission of his gastric lymphoma (fig. [6](#F6){ref-type="fig"}).

Discussion {#sec1_3}
==========

One-third of non-Hodgkin lymphomas arise primarily from extranodal sites. Gastrointestinal tract involvement is the most common, with the stomach ahead of the small bowel \[[@B16]\]. Primary gastric lymphoma is an evolving pathology that remains rare (less than 5%) compared to other stomach malignancies. The vast majority is made of either diffuse large B cell or MALT phenotypes \[[@B17]\]. The latter is known to be induced by *H. pylori*. Eradication of this microorganism is usually curative. PG-DLBCL, on the other hand, has a less defined relationship with *H. pylori*. Some authors propose that a substantial portion of early-stage 'de novo' PG-DLBCLs are *H. pylori*-dependent and will respond well to *H. pylori* eradication \[[@B18]\]. PG-DLBCL can present as an aggressive fast-growing tumor. It can have a variety of symptoms including fatigue, anorexia, weight loss and abdominal pain. Tumor infiltration within the stomach wall can be complicated by major bleeding \[[@B19]\], gastric perforation \[[@B20]\] or even fistula formation with adjacent structures \[[@B21]\].

Diagnosing PG-DLBCL always involves multiple investigations. Besides clinical presentation and non-specific serum lymphocytosis, imaging modalities usually provide evidence of possible stomach involvement. Abdominal ultrasound, CT or MRI may show gastric wall thickening with or without intra-abdominal lymph nodes. Some authors advocate using endoscopic ultrasound for imaging and staging gastric lymphoma \[[@B22]\]. The staging process of PG-DLBCL is still being debated. It involves multiple clinical, serologic and radiologic parameters such as age, serum albumin and evidence of disease dissemination \[[@B23]\]. Developing improved diagnostic tools will shed further light on the complex nature of this disease.

PG-DLBCL is usually fatal if left untreated. The standard combination chemotherapy for large B cell lymphoma is the CHOP regimen: cyclophosphamide, doxorubicin, vincristine and prednisolone. As in our case, other agents such as etoposide and rituximab can be added.

A recent study showed that adding rituximab to the CHOP combination did not impact the patients' cure rate \[[@B24]\]. Our patient did extremely well with eight cycles of R-CHOEP (R: rituximab, E: etoposide) and had an excellent response to the therapeutic management despite the unusually large size of his gastric ulcer. Follow-up CT, endoscopy and tissue biopsy showed evidence of complete remission of his gastric lymphoma. Besides the patient\'s good performance status, low serum lactate dehydrogenase levels are associated with longer disease-free survival \[[@B25]\].

Conclusions {#sec1_4}
===========

PG-DLBCL is an evolving pathology. Indeed, its *H. pylori* dependence and staging are still being developed. Modern diagnostic radiologic, endoscopic and histopathologic tools are shedding further light on the complexity of this disease. While CHOP is widely used to treat this condition, other therapeutic interventions are being explored. Ongoing and future research will likely bring forth new ways to understand and manage this unique form of lymphoma.
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![CT scan of the abdomen showing diffuse asymmetric wall thickening of the pylorus and antrum (arrow).](crg-0008-0134-g01){#F1}

![Upper endoscopic view of a large friable ulcer occupying most of the gastric antrum.](crg-0008-0134-g02){#F2}

![**a** Low-magnification view of the stomach ulcer (H&E stain, ×100). Invasion of the gastric lamina propria by sheets of medium to large atypical lymphoid cells (asterisks), compared to uninvolved areas (arrow) with sparse reactive inflammatory infiltrates. **b** High-magnification view of the atypical lymphoid infiltrates (CD20 IHC stain, ×200). Diffuse cytoplasmic staining of the atypical lymphocytic infiltrates (asterisks) for anti-CD20 marker, indicating B lymphocyte cell origin.](crg-0008-0134-g03){#F3}

![Repeat CT scan of the abdomen post treatment. No visible thickening of the stomach wall (arrow).](crg-0008-0134-g04){#F4}

![Repeat endoscopic view post treatment. Normal appearance of the antrum and pylorus.](crg-0008-0134-g05){#F5}

![Low-magnification view of the previous ulcer site post treatment (H&E stain, ×100). No histopathologic evidence of residual tumor.](crg-0008-0134-g06){#F6}
